Literature DB >> 12729622

Mutation of active site residues of the puromycin-sensitive aminopeptidase: conversion of the enzyme into a catalytically inactive binding protein.

Michael W Thompson1, Meera Govindaswami, Louis B Hersh.   

Abstract

The active site glutamate, Glu 309, of the puromycin-sensitive aminopeptidase was mutated to glutamine, alanine, and valine. These mutants were characterized with amino acid beta-naphthylamides as substrates and dynorphin A(1-9) as an alternate substrate inhibitor. Conversion of glutamate 309 to glutamine resulted in a 5000- to 15,000-fold reduction in catalytic activity. Conversion of this residue to alanine caused a 25,000- to 100,000-fold decrease in activity, while the glutamate to valine mutation was the most dramatic, reducing catalytic activity 300,000- to 500,000-fold. In contrast to the dramatic effect on catalysis, all three mutations produced relatively small (1.5- to 4-fold) effects on substrate binding affinity. Mutation of a conserved tyrosine, Y394, to phenylalanine resulted in a 1000-fold decrease in k(cat), with little effect on binding. Direct binding of a physiological peptide, dynorphin A(1-9), to the E309V mutant was demonstrated by gel filtration chromatography. Taken together, these data provide a quantitative assessment of the effect of mutating the catalytic glutamate, show that mutation of this residue converts the enzyme into an inactive binding protein, and constitute evidence that this residue acts a general acid/base catalyst. The effect of mutating tyrosine 394 is consistent with involvement of this residue in transition state stabilization.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12729622     DOI: 10.1016/s0003-9861(03)00123-1

Source DB:  PubMed          Journal:  Arch Biochem Biophys        ISSN: 0003-9861            Impact factor:   4.013


  16 in total

1.  The closed structure of presequence protease PreP forms a unique 10,000 Angstroms3 chamber for proteolysis.

Authors:  Kenneth A Johnson; Shashi Bhushan; Annelie Ståhl; B Martin Hallberg; Anne Frohn; Elzbieta Glaser; Therese Eneqvist
Journal:  EMBO J       Date:  2006-04-06       Impact factor: 11.598

2.  Tat peptides inhibit neprilysin.

Authors:  Abigail Daily; Avindra Nath; Louis B Hersh
Journal:  J Neurovirol       Date:  2006-06       Impact factor: 2.643

Review 3.  Genetic associations and functional characterization of M1 aminopeptidases and immune-mediated diseases.

Authors:  N Agrawal; M A Brown
Journal:  Genes Immun       Date:  2014-08-21       Impact factor: 2.676

4.  Peracetylated N-acetylmannosamine, a synthetic sugar molecule, efficiently rescues muscle phenotype and biochemical defects in mouse model of sialic acid-deficient myopathy.

Authors:  May Christine V Malicdan; Satoru Noguchi; Tomoharu Tokutomi; Yu-ichi Goto; Ikuya Nonaka; Yukiko K Hayashi; Ichizo Nishino
Journal:  J Biol Chem       Date:  2011-12-08       Impact factor: 5.157

5.  Circulating neprilysin clears brain amyloid.

Authors:  Yinxing Liu; Christa Studzinski; Tina Beckett; M Paul Murphy; Ronald L Klein; Louis B Hersh
Journal:  Mol Cell Neurosci       Date:  2010-06-15       Impact factor: 4.314

Review 6.  Brain-specific aminopeptidase: from enkephalinase to protector against neurodegeneration.

Authors:  Koon-Sea Hui
Journal:  Neurochem Res       Date:  2007-05-03       Impact factor: 3.996

7.  Aminopeptidases do not directly degrade tau protein.

Authors:  K Martin Chow; Hanjun Guan; Louis B Hersh
Journal:  Mol Neurodegener       Date:  2010-11-05       Impact factor: 14.195

8.  Expression of neprilysin in skeletal muscle reduces amyloid burden in a transgenic mouse model of Alzheimer disease.

Authors:  Yinxing Liu; Christa Studzinski; Tina Beckett; Hanjun Guan; Matthew A Hersh; M Paul Murphy; Ronald Klein; Louis B Hersh
Journal:  Mol Ther       Date:  2009-05-26       Impact factor: 11.454

9.  An enzymatic toolkit for selective proteolysis, detection, and visualization of mucin-domain glycoproteins.

Authors:  D Judy Shon; Stacy A Malaker; Kayvon Pedram; Emily Yang; Venkatesh Krishnan; Oliver Dorigo; Carolyn R Bertozzi
Journal:  Proc Natl Acad Sci U S A       Date:  2020-08-17       Impact factor: 11.205

10.  Peripherally expressed neprilysin reduces brain amyloid burden: a novel approach for treating Alzheimer's disease.

Authors:  Hanjun Guan; Yinxing Liu; Abigail Daily; Sara Police; Myung-Hee Kim; Salvatore Oddo; Frank M LaFerla; James R Pauly; M Paul Murphy; Louis B Hersh
Journal:  J Neurosci Res       Date:  2009-05-01       Impact factor: 4.164

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.